IJM:MYXIJM Corporation Berhad Analysis
Data as of 2026-06-19 - not real-time
€42.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Athos Immobilien AG is trading at €42, just above its 20‑day (40.2) and 50‑day (40.08) simple moving averages, indicating a modest short‑term bullish bias. However, the RSI sits at an extreme 99.9, flagging severe overbought conditions, and the MACD histogram remains positive, creating a mixed technical picture. Fundamentally, the stock is dramatically overvalued with a trailing PE of 381 versus an industry average of 32, while profit margins are thin (2.2%) and ROE is only 0.4%, suggesting earnings are not supporting the price. The dividend yield of 2% appears sustainable thanks to a very low payout ratio of 7%, but the company carries a massive debt load (≈ €60.9 M) and a debt‑to‑equity ratio of 125, raising balance‑sheet concerns. Recent material news reports the outcome of a share‑buyback offer and a capital reduction, which could improve per‑share metrics but also signal limited cash resources (total cash €52,923). Volatility over the past 30 days is moderate at 14%, beta is essentially neutral (‑0.015), yet trading volume is effectively zero, exposing significant liquidity risk. The combination of an overbought technical stance, extreme valuation, weak profitability, and thin liquidity suggests caution, even though the dividend remains modestly attractive.
Investors should weigh the short‑term price pressure from the buyback against the long‑term challenges of high leverage and limited earnings growth before deciding on exposure.
Investors should weigh the short‑term price pressure from the buyback against the long‑term challenges of high leverage and limited earnings growth before deciding on exposure.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- RSI at 99.9 indicating extreme overbought condition
- Trailing PE of 381 far above industry norm
- Near‑zero trading volume creating liquidity constraints
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Share‑buyback and capital reduction could modestly support price
- Sustainable dividend with low payout ratio
- Persistent high debt levels limiting earnings upside
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Fundamental overvaluation remains unattractive
- Weak profitability and low ROE
- Stable but modest dividend yield offering limited total return
Key Metrics & Analysis
Financial Health
Revenue Growth6.10%
Profit Margin2.19%
P/E Ratio381.8
ROE0.40%
ROA0.94%
Debt/Equity125.27
P/B Ratio1.5
Industry P/E32.3
Technical Analysis
TrendNeutral
RSI99.9
Support€40.00
Resistance€42.00
MA 20€40.20
MA 50€40.08
MA 200€41.36
MACDBullish
VolumeStable
Fear & Greed Index92.14
Valuation
GradeOvervalued
TypeValue
Dividend Yield2.00%
Risk Assessment
Beta-0.02
Volatility14.14%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.